Anthropic's IPO push includes a big bet on life sciences
Source: Business Insider ·
Anthropic's S-1 filing says Claude can accelerate drug discovery and biology research, making life sciences central to the AI company's IPO pitch.
From the source
Vas Narasimhan, CEO of the pharma giant Novartis, joined Anthropic's board of directors in April.Hollie Adams/Bloomberg via Getty ImagesAnthropic is starting to think like a drugmaker.Anthropic's IPO filing outlines its ambitious plans for biological science.AI in scientific research would aid Anthropic's mission and boost adoption of its Claude models.Anthropic conquered coding. Now it's setting its sights on the human body.Anthropic's S-1 filing, which outlines its ambitions and financials ahead of a massive initial public offering next month, reads as a life-sciences manifesto. The maker of Claude sees itself as a crucial cog in the next generation of biological and medicinal research — and is selling that lucrative vision to its would-be investors.Anthropic is hoping for a wave of new discoveries that will support its do-gooder mission and convince the public of AI's power and worth. Its life-science focus could also support financial growth beyond its AI software engineering…